MedTrace Logo

A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis

NCT00492700 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2007-06-27

No results posted yet for this study

Summary

This study is intended to find out whether treatment with rosiglitazone improves the state of the liver and related blood markers in patients with nonalcoholic steatohepatitis (NASH).

Conditions

  • Non Alcoholic Steatohepatitis

Interventions

DRUG

rosiglitazone

Sponsors & Collaborators

  • Association pour la Recherche sur les Maladies Hépatiques Virales

    lead OTHER

Principal Investigators

  • Vlad Ratziu, MD PhD · Hôpital Pitié Salpêtrière, APHP

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00492700 on ClinicalTrials.gov